11月26日上午，诚意药业（603811.SH）通过上证路演平台召开2025年第三季度业绩说明会，公司总经 理赵春建、销售副总经理颜丽娜、研发副总经理罗飞跃等六位高管通过线上方式，同投资者积极沟通， 围绕公司战略进展、业绩表现、氨糖产品市场情况等投资者关切问题进行回复与解答，展现了公司深耕 主业、有序推进"两强一大"的战略方针与对远期业绩增长的强大信心。 鱼油EPA软胶囊获批 大健康产业布局提速 诚意药业是"海洋药物"头部企业，专注于医药健康产品及原料药的研发、生产和销售，产品覆盖关节 类、利尿降压类、抗病毒类等多种药物，其主打产品盐酸氨基葡萄糖胶囊（维尔固）可修复退变软骨， 疗效良好，获得市场一致认可。 氨糖产品营收稳健增长 OTC省代助力利润扩增 公司业绩的亮眼表现同样被高度关注，数据显示，2025年前三季度公司关节类药物营收4.92亿元，同比 增长42.23%，占公司总营收比重达80%以上。作为关节类产品的核心，公司氨糖产品居市场领先地位， 自2020年国采"以价换量"以来仍以每年10%以上的增速稳步增长，尤其近两年在公司渠道改革及销售强 化的推动下，2025年起增速重回40%以上。 管理层表示，成本价 ...

Core Viewpoint - The company, Zhejiang Chengyi Pharmaceutical Co., Ltd., reported a revenue of 714.37 million yuan for the year 2024, reflecting a growth of 6.36% compared to the previous year, with a net profit attributable to shareholders of 200.70 million yuan, an increase of 23.21% [11][12]. Group 1: Company Overview - The company specializes in the research, development, production, and sales of pharmaceutical health products, holding 81 drug production approval numbers and raw material drug registration numbers, with 47 products included in the national medical insurance catalog [8]. - The main products include glucosamine hydrochloride capsules, which are well-received in the market, particularly for treating osteoarthritis, and have achieved a market share of over 41% in nine provinces [6][8]. Group 2: Financial Performance - The company achieved a revenue of 714.37 million yuan, a 6.36% increase year-on-year, and a net profit of 200.70 million yuan, marking a 23.21% growth compared to the previous year [11][12]. - The proposed profit distribution plan includes a cash dividend of 2.50 yuan per 10 shares, amounting to a total distribution of approximately 79.42 million yuan [4]. Group 3: Industry Context - The pharmaceutical manufacturing industry is a significant part of China's economy, driven by increasing healthcare demands due to rising living standards and an aging population [5]. - The company is responding to national initiatives to develop the marine economy by leveraging raw material advantages to create marine biological pharmaceutical products [6].